LGND

Ligand Pharmaceuticals Inc

May 21 • 04:00PM ET

222.18

+4.43 2.03 %

Healthcare • Biotechnology • USA • Mid • NASD

| Held by: IJR VTI VB IWM VBR VXF SPSM IJT XSMO IWN

Index	RUT	P/E	30.12	EPS (ttm)	7.38	Insider Own	2.57%	Shs Outstand	20.03M	Perf Week	1.46%
Market Cap	4.45B	Forward P/E	19.91	EPS next Y	11.16	Insider Trans	-7.76%	Shs Float	19.53M	Perf Month	-2.07%
Enterprise Value	4.13B	PEG	1.20	EPS next Q	2.01	Inst Own	104.62%	Short Float	7.45%	Perf Quarter	20.76%
Income	153.56M	P/S	16.22	EPS this Y	11.35%	Inst Trans	-0.13%	Short Ratio	6.39	Perf Half Y	7.31%
Sales	274.48M	P/B	4.46	EPS next Y	23.30%	ROA	12.60%	Short Interest	1.46M	Perf YTD	17.51%
Book/sh	49.79	P/C	5.71	EPS next 5Y	16.58%	ROE	17.13%	52W High	247.38 -10.19%	Perf Year	116.87%
Cash/sh	38.89	P/FCF	36.17	EPS past 3/5Y	- -	ROIC	10.60%	52W Low	98.89 124.67%	Perf 3Y	198.83%
Dividend Est.	-	EV/EBITDA	30.39	Sales past 3/5Y	10.96% 7.54%	Gross Margin	83.42%	Volatility	3.61% 4.42%	Perf 5Y	181.10%
Dividend TTM	-	EV/Sales	15.03	EPS Y/Y TTM	210.12%	Oper. Margin	36.88%	ATR (14)	9.65	Perf 10Y	191.79%
Dividend Ex-Date	Jul 02, 2010	Quick Ratio	20.95	Sales Y/Y TTM	51.24%	Profit Margin	55.95%	RSI (14)	52.42	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	21.28	EPS Q/Q	69.66%	SMA20	-0.45%	Beta	1.21	Target Price	270.67
Payout	0.00%	Debt/Eq	0.45	Sales Q/Q	14.09%	SMA50	3.00%	Rel Volume	0.68	Prev Close	217.75
Employees	47	LT Debt/Eq	0.45	Earnings	May 07 BMO	SMA200	15.12%	Avg Volume	227.57K	Price	222.18
IPO	Nov 18, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	-10.23% -11.88%	Trades		Volume	153,830	Change	2.03%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-26	Initiated	BofA Securities	Buy	$244
Dec-09-25	Initiated	Citigroup	Buy	$270
Apr-10-25	Initiated	Stifel	Buy	$143
Oct-03-24	Initiated	Oppenheimer	Outperform	$135
Jul-30-24	Initiated	RBC Capital Mkts	Outperform	$130
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral

Show Previous Ratings

May-07-26 07:28AM	Ligand: Q1 Earnings Snapshot (Associated Press) -9.55%
07:00AM	Ligand Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-05-26 04:01PM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-27-26 10:19AM	Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal (Investor's Business Daily)
09:10AM	Ligand Pharmaceuticals buying Xoma Royalty for $739 million (Quartz)
07:00AM	Loading…
07:00AM	Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator (GlobeNewswire)
06:00AM	Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million (The Wall Street Journal)
Apr-22-26 07:00AM	Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Apr-14-26 07:00AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan) in FSGS (GlobeNewswire) +8.85%
Mar-26-26 07:00AM	Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team (GlobeNewswire)
Mar-12-26 04:25PM	How A Broad Sell-Off Rattled Top 3% Breakout Stock Ligand Pharma (Investor's Business Daily)
Mar-11-26 01:49PM	Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says (Proactive)
09:40AM	Oracle, Nike upgraded: Wall Street's top analyst calls (The Fly)
07:45AM	Here Are Wednesday's Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More (24/7 Wall St.)
06:11AM	Ligand initiated with a Buy at BofA (TipRanks)
05:14PM	Loading…
Mar-10-26 05:14PM	IBD Stock Of The Day: Ligand Pharma, Biotech's Royalty Arm, Breaks Out (Investor's Business Daily)
Mar-06-26 12:47PM	This Pharma Stock Shows Strength, Eyes Entry As Earnings Surge 59% (Investor's Business Daily)
09:12AM	These Are The 5 Best Stocks To Buy Or Watch Now (Investor's Business Daily)
Mar-04-26 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire)
Feb-26-26 05:03PM	Ligand Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
04:10PM	Ligand Pharmaceuticals Inc (LGND) Q4 2025 Earnings Call Highlights: Surpassing Expectations and ... (GuruFocus.com)
07:50AM	Ligand: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-23-26 04:10PM	Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J (Investor's Business Daily)
08:44AM	Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal (Investor's Business Daily)
Feb-12-26 07:00AM	Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Feb-04-26 07:00AM	Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-26 12:39PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
Jan-13-26 04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily) -8.72%
Jan-12-26 10:32AM	Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026 (Barchart)
07:13AM	Loading…
Jan-08-26 07:13AM	Dow Jones Futures Fall; Lockheed, Defense Giants Bounce On $1.5 Trillion Trump 'Dream Military' (Investor's Business Daily)
Jan-07-26 05:05PM	Dow Jones Futures: Stock Market Fades From Highs; Eli Lilly, Google Lead New Buys (Investor's Business Daily)
Dec-09-25 07:00AM	Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance (GlobeNewswire)
Nov-20-25 01:34PM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year (Investor's Business Daily)
Nov-19-25 08:11AM	What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? (Insider Monkey)
Nov-18-25 08:03AM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year (Investor's Business Daily)
Nov-10-25 05:31AM	Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer (Pharmaceutical Technology)
Nov-06-25 07:14AM	Ligand: Q3 Earnings Snapshot (Associated Press Finance) +9.37%
07:00AM	Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Oct-30-25 04:01PM	Ligand to Participate in November Investor Conferences (GlobeNewswire)
Oct-23-25 07:00AM	Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	Ligand to Host Investor Day on December 9, 2025 (GlobeNewswire)
Oct-09-25 07:00AM	Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients (GlobeNewswire)
Aug-19-25 04:00PM	Ligand to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-25 04:00PM	Ligand Announces Closing of Convertible Senior Notes Offering (GlobeNewswire)
Aug-12-25 08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-11-25 11:46PM	Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering (GlobeNewswire)
07:00AM	Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 (GlobeNewswire)
Aug-07-25 07:24AM	Ligand: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Jul-31-25 04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-24-25 07:00AM	Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-17-25 02:10PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily) +6.13%
Jul-12-25 02:00PM	Top 3 small-cap stock picks while navigating trade uncertainty (Yahoo Finance Video)
Jul-10-25 10:43AM	LGND Raises $9M to Make Earth Data Intuitive and Actionable (PR Newswire)
09:58AM	LGND wants to make ChatGPT for the Earth (TechCrunch)
08:00AM	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI (GlobeNewswire)
Jul-03-25 07:17AM	Ligands LNHC concludes merger with CHRO (Pharmaceutical Technology)
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire)
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)
Jun-11-25 07:00AM	Ligand Announces 2025 Investor Day in New York City (GlobeNewswire)
May-14-25 07:00AM	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 (GlobeNewswire)
May-08-25 07:44AM	Ligand Pharmaceuticals Reiterates FY25 Outlook - Update (RTT News)
07:00AM	Ligand Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:09PM	Ligand Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 07:00AM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-24-25 07:00AM	Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-20-25 09:35AM	Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 (Seeking Alpha)
Apr-17-25 06:00AM	Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics (GlobeNewswire)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha) -5.17%
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-25 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire) -8.22%
Feb-27-25 07:00AM	Ligand Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:00AM	Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences (GlobeNewswire)
Feb-13-25 07:00AM	Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (Business Wire)
Feb-06-25 07:00AM	Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-12-24 07:45AM	Ligand price target raised to $151 from $135 at Oppenheimer (TipRanks) -5.69%
Dec-10-24 09:00AM	Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance (Business Wire)
Nov-14-24 08:00AM	Ligand to Present at Stifel 2024 Healthcare Conference (Business Wire) -5.43%
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire) +11.12%
Nov-01-24 08:01AM	Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (Business Wire)
Oct-23-24 04:01PM	Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-17-24 07:30AM	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer (GlobeNewswire)
Sep-06-24 09:20AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Business Wire)
Aug-20-24 09:00AM	Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-06-24 04:01PM	Ligand Reports Second Quarter 2024 Financial Results (Business Wire) -5.78%
Jul-24-24 06:30AM	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement (ACCESSWIRE)
Jul-23-24 04:01PM	Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jul-08-24 07:00AM	Ligand to Acquire APEIRON Biologics AG for $100 Million (Business Wire)
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
Jun-27-24 08:00AM	Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years (Business Wire) +5.80%
Jun-18-24 08:00AM	Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Adults (Business Wire)
Jun-14-24 12:00PM	What Makes Ligand (LGND) a New Strong Buy Stock (Zacks)
Jun-06-24 11:31AM	Why Is Ligand (LGND) Up 4% Since Last Earnings Report? (Zacks)
Jun-04-24 09:55AM	Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect? (Zacks) -8.05%
08:50AM	Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why (Zacks)
May-23-24 04:59PM	Ligand to Participate in Upcoming Investor Conferences (Business Wire)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

CEO & DirectorMr. Todd C. Davis Ph.D.

Chief Financial OfficerMr. Octavio Espinoza

Chief Legal Officer & SecretaryMr. Andrew T. Reardon J.D.

Senior Vice President of Investments & Business DevelopmentMr. Paul J. Hadden

Executive Director of Investor Relations and Financial Planning & AnalysisMs. Melanie J. Herman CPA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KOZARICH JOHN W	Director	May 13 '26	Option Exercise	69.51	1,575	109,478	43,361	May 14 09:08 PM
KOZARICH JOHN W	Director	May 12 '26	Option Exercise	69.51	459	31,905	42,245	May 14 09:08 PM
KOZARICH JOHN W	Director	May 13 '26	Sale	223.50	1,575	352,012	41,786	May 14 09:08 PM
KOZARICH JOHN W	Director	May 01 '26	Sale	231.80	467	108,251	41,786	May 14 09:08 PM
KOZARICH JOHN W	Director	May 12 '26	Sale	224.00	459	102,816	41,786	May 14 09:08 PM
JOHN KOZARICH	Director	May 13 '26	Proposed Sale	223.50	1,575	352,012		May 13 04:09 PM
JOHN KOZARICH	Director	May 12 '26	Proposed Sale	224.00	459	102,816		May 12 05:45 PM
Reardon Andrew	CLO & Secretary	May 01 '26	Option Exercise	52.27	5,000	261,350	46,382	May 04 08:20 PM
Reardon Andrew	CLO & Secretary	May 01 '26	Sale	231.31	5,000	1,156,556	41,382	May 04 08:20 PM
KOZARICH JOHN W	Director	May 01 '26	Proposed Sale	229.87	467	107,349		May 01 04:16 PM
KOZARICH JOHN W	Director	Apr 01 '26	Sale	202.23	467	94,440	42,253	Apr 02 07:43 PM
Reardon Andrew	CLO & Secretary	Apr 01 '26	Option Exercise	52.27	5,000	261,350	46,382	Apr 02 06:56 PM
Reardon Andrew	CLO & Secretary	Apr 01 '26	Sale	201.24	5,000	1,006,224	41,382	Apr 02 06:56 PM
KOZARICH JOHN W	Director	Apr 01 '26	Proposed Sale	203.50	467	95,034		Apr 01 04:10 PM
LAMATTINA JOHN L	Director	Mar 06 '26	Option Exercise	114.15	2,161	246,678	32,885	Mar 31 05:53 PM
LAMATTINA JOHN L	Director	Mar 06 '26	Sale	200.76	2,161	433,842	30,724	Mar 31 05:53 PM
Sabba Stephen L	Director	Mar 23 '26	Sale	207.87	1,000	207,873	32,793	Mar 25 11:13 AM
STEPHEN L. SABBA	Director	Mar 23 '26	Proposed Sale	207.87	1,000	207,873		Mar 23 04:04 PM
Espinoza Octavio	Chief Financial Officer	Mar 11 '26	Option Exercise	92.65	2,405	222,823	24,067	Mar 13 07:29 PM
Espinoza Octavio	Chief Financial Officer	Mar 11 '26	Sale	225.00	3,057	687,825	21,010	Mar 13 07:29 PM
OCTAVIO ESPINOZA	Officer	Mar 11 '26	Proposed Sale	212.29	3,057	648,971		Mar 11 04:42 PM
Reardon Andrew	CLO & Secretary	Mar 04 '26	Option Exercise	52.27	5,000	261,350	41,869	Mar 06 06:51 PM
Reardon Andrew	CLO & Secretary	Mar 04 '26	Sale	206.35	5,000	1,031,770	36,869	Mar 06 06:51 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '26	Option Exercise	63.49	2,073	131,609	35,085	Mar 06 06:49 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '26	Sale	205.83	13,423	2,762,822	21,662	Mar 06 06:49 PM
JOHN L LAMATTINA	Director	Mar 06 '26	Proposed Sale	200.76	2,161	433,842		Mar 06 04:17 PM
Sabba Stephen L	Director	Mar 03 '26	Option Exercise	69.51	2,034	141,383	35,827	Mar 05 11:05 AM
Sabba Stephen L	Director	Mar 03 '26	Sale	201.50	2,034	409,851	33,793	Mar 05 11:05 AM
KOZARICH JOHN W	Director	Mar 02 '26	Sale	200.50	467	93,632	42,720	Mar 04 09:04 PM
ANDREW REARDON	Officer	Mar 04 '26	Proposed Sale	204.24	20,000	4,084,800		Mar 04 04:44 PM
OCTAVIO ESPINOZA	Officer	Mar 04 '26	Proposed Sale	204.24	13,423	2,741,514		Mar 04 04:39 PM
STEPHEN L. SABBA	Director	Mar 03 '26	Proposed Sale	201.50	2,034	409,851		Mar 03 04:27 PM
KOZARICH JOHN W	Director	Feb 02 '26	Sale	195.91	467	91,490	43,187	Feb 04 05:18 PM
KOZARICH JOHN W	Director	Feb 02 '26	Proposed Sale	192.18	467	89,748		Feb 02 04:12 PM
KOZARICH JOHN W	Director	Jan 02 '26	Sale	189.58	467	88,532	43,654	Jan 06 07:47 PM
KOZARICH JOHN W	Director	Jan 02 '26	Proposed Sale	188.60	467	88,076		Jan 02 04:04 PM
Espinoza Octavio	Chief Financial Officer	Dec 16 '25	Option Exercise	69.00	2,381	164,298	28,567	Dec 18 04:19 PM
Espinoza Octavio	Chief Financial Officer	Dec 12 '25	Sale	188.31	1,804	339,711	26,186	Dec 16 06:36 PM
OCTAVIO ESPINOZA	Officer	Dec 12 '25	Proposed Sale	188.31	1,804	339,711		Dec 12 05:22 PM
Aryeh Jason	Director	Dec 08 '25	Option Exercise	69.51	2,034	141,383	71,323	Dec 08 07:38 PM
KOZARICH JOHN W	Director	Dec 01 '25	Sale	195.84	467	91,457	44,121	Dec 03 05:08 PM
KOZARICH JOHN W	Director	Dec 01 '25	Proposed Sale	199.88	467	93,344		Dec 01 04:08 PM
Gray Nancy Ryan	Director	Nov 07 '25	Option Exercise	69.58	6,571	457,185	11,650	Nov 12 04:45 PM
Gray Nancy Ryan	Director	Nov 07 '25	Sale	205.45	6,571	1,350,012	8,094	Nov 12 04:45 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Option Exercise	67.78	4,179	283,232	32,869	Nov 12 04:44 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Sale	205.45	4,179	858,576	30,724	Nov 12 04:44 PM
NANCY GRAY	Director	Nov 07 '25	Proposed Sale	205.45	6,571	1,350,012		Nov 07 05:05 PM
JOHN L LAMATTINA	Director	Nov 07 '25	Proposed Sale	205.45	4,179	858,576		Nov 07 04:05 PM
KOZARICH JOHN W	Director	Nov 03 '25	Sale	191.05	467	89,219	44,588	Nov 05 05:22 PM
KOZARICH JOHN W	Director	Nov 03 '25	Proposed Sale	191.05	467	89,219		Nov 03 04:05 PM
KOZARICH JOHN W	Director	Oct 01 '25	Sale	179.44	467	83,800	45,055	Oct 03 04:45 PM
KOZARICH JOHN W	Director	Oct 01 '25	Proposed Sale	176.68	467	82,510		Oct 01 04:09 PM
Aryeh Jason	Director	Sep 23 '25	Sale	170.81	10,000	1,708,088	69,289	Sep 24 05:11 PM
JASON M ARYEH	Director	Sep 23 '25	Proposed Sale	170.81	10,000	1,708,087		Sep 23 04:50 PM
Aryeh Jason	Director	Sep 17 '25	Proposed Sale	168.50	10,000	1,685,000		Sep 17 12:41 PM
KOZARICH JOHN W	Director	Sep 02 '25	Sale	162.26	467	75,775	45,522	Sep 04 05:47 PM
KOZARICH JOHN W	Director	Sep 02 '25	Proposed Sale	161.71	467	75,518		Sep 02 04:16 PM
KOZARICH JOHN W	Director	Aug 01 '25	Sale	131.88	467	61,586	45,989	Aug 05 05:03 PM
KOZARICH JOHN W	Director	Aug 01 '25	Proposed Sale	131.00	467	61,177		Aug 01 04:04 PM
KOZARICH JOHN W	Director	Jul 10 '25	Sale	125.00	934	116,750	46,456	Jul 11 06:17 PM
KOZARICH JOHN W	Officer	Jul 10 '25	Proposed Sale	125.00	934	116,750		Jul 10 05:08 PM
Reardon Andrew	CLO & Secretary	Jun 23 '25	Sale	114.08	500	57,042	31,903	Jun 24 08:29 PM
ANDREW THOMAS REARDON	Officer	Jun 23 '25	Proposed Sale	114.08	500	57,042		Jun 23 05:07 PM
Reardon Andrew	CLO & Secretary	Jun 10 '25	Sale	114.54	500	57,271	32,403	Jun 12 05:51 PM
ANDREW THOMAS REARDON	Officer	Jun 10 '25	Proposed Sale	114.54	500	57,271		Jun 10 06:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LGND

Ligand Pharmaceuticals Inc

Upgrade your Finviz experience